Zai Lab (ZLAB) investor relations material

Executive summary

• Achieved total revenue of $460.2M for FY25, up 15% year-over-year, with Q4 revenue at $127.6M, up 17% year-over-year, driven by strong product sales, especially XACDURO and NUZYRA, and commercial execution in China.

• Advanced global oncology and immunology pipeline, with Zoci moving from IND to global phase III in under two years and aiming for first U.S. approval by 2028; over nine indications in development by 2030.

• Maintained a robust cash position of $790M at year-end 2025.

• Focus for 2026 is on execution, pipeline catalysts, and preparation for multiple product launches, with profitability as a key objective.

Financial highlights

• Product revenue for FY25 reached $457.2M, up 15% year-over-year; Q4 product revenue was $127.1M, up 17%.

• Notable product growth: XACDURO up 225–593% year-over-year, NUZYRA up 41–45%, ZEJULA up 16%, QINLOCK up 24%, OPTUNE up 19%.

• Adjusted operating loss for FY25 was $(148.8)M, a 25% improvement from $(199.6)M in FY24; net loss narrowed to $175.5M for the year.

• R&D expenses declined 6% for the full year to $220.9M; SG&A expenses decreased 7% to $277.6M.

• Ended the year with $789.6M in cash and equivalents.

Outlook and guidance

• 2026 is a transition year with continued top-line growth expected, driven by VYVGART, ZEJULA, XACDURO, and new launches like COBENFY and TIVDAK.

• Multiple pivotal data readouts and regulatory submissions expected in 2026 for key pipeline assets; first U.S. approval targeted by 2028.

• SG&A and R&D expenses expected to remain flat or grow modestly; focus on operational efficiency and disciplined investment.

• No full-year guidance provided due to pricing, rebate, and hospital purchasing uncertainties.